Jinhai Medical Technology Limited (“Jinhai Med Tech”) filed its Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 31 July 2026, highlighting a steady share capital position and continued compliance with public-float requirements.
Authorised and Issued Share Capital • Authorised capital remained unchanged at 8.00 billion ordinary shares with a par value of HKD 0.0025, equivalent to HKD 20.00 million. • Issued share capital totalled 5.30 billion ordinary shares, identical to the previous month. The company held no treasury shares, and there were no share issuances, cancellations, or buy-backs during July.
Public Float Compliance • As at 31 July 2026, Jinhai Med Tech confirmed compliance with the Main Board’s minimum public-float threshold of 25%.
Equity-Based Incentives • The Share Option Scheme adopted on 29 December 2023 had 445.96 million outstanding options, unchanged during the month. No options were exercised, and no new shares were issued under the scheme. • No warrants, convertible securities, or other equity-linked instruments were outstanding or exercised.
Corporate Governance Confirmation The company’s submission, signed by the Company Secretary, attested that all securities matters during the month adhered to Hong Kong Listing Rules and other regulatory requirements.
Overall, Jinhai Med Tech’s July 2026 return reflects a period of capital stability, with unchanged share counts and maintained regulatory compliance.
Comments